Last updated on June 2019

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers


Brief description of study

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Detailed Study Description

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, an intravenous PD-L1 inhibitor. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Clinical Study Identifier: NCT02655822

Find a site near you

Start Over

UCLA Medical Center

Los Angeles, CA United States
  Connect »

Stanford Cancer Institute

Stanford, CA United States
  Connect »

Yale University

New Haven, CT United States
  Connect »

Georgetown University

Washington, WA United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Carolina BioOncology Institute

Huntersville, NC United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Monash Health

Clayton, Australia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.